Effects of the pyruvate kinase activator mitapivat on ATP levels in SCD

Overview

This study investigates the effects of mitapivat on ATP levels and red blood cell adhesiveness in healthy individuals and patients with sickle cell disease (SCD). Mitapivat increased ATP levels in healthy red blood cells, but did not significantly affect ATP levels in SCD red blood cells under the same conditions.

Background

Sickle cell disease (SCD) is characterized by hemolytic anemia and vaso-occlusive crises, leading to significant morbidity and mortality. Red blood cells (RBCs) in SCD patients exhibit reduced ATP levels, impacting their functionality and contributing to disease complications. Understanding the role of ATP in RBCs is crucial for developing effective treatments for SCD.

Data Highlights

Key Findings

• Mitapivat treatment increased intra-RBC ATP in healthy controls but not in SCD RBCs.
• Exported ATP from healthy RBCs increased under hypoxic conditions.
• Exported ATP from SCD RBCs increased in hypoxia compared to normoxia.
• Mitapivat did not significantly change ATP export from SCD RBCs.
• SS RBC adhesion to laminin decreased after exposure to mitapivat at physiologically relevant shear stresses.

Clinical Implications

The findings suggest that while mitapivat may enhance ATP levels in healthy RBCs, its efficacy in SCD RBCs remains limited. Clinicians should consider these differences when evaluating treatment options for SCD patients.

Conclusion

Mitapivat shows promise in increasing ATP levels in healthy RBCs but does not significantly affect SCD RBCs, highlighting the need for further research in this area.

Related Resources & Content

1. ASH SCD Guidelines: Transfusion Support - Hematology.org, 2024 -- Clinical Practice Guidelines
2. Safety and efficacy of mitapivat in sickle cell disease (RISE UP), ScienceDirect, 2024 -- Phase 2 trial results
3. Knee Surgery, Sports Traumatology, Arthroscopy — Elevated pyruvate levels following Achilles tendon rupture surgery may serve as a prognostic indicator for enhanced patient recovery outcomes
4. Archives of Toxicology — Safety Evaluation of Systemic Pathway Disruptions Through Multi-Omic Analysis Following In Vivo Inhibition of MAT2A
5. Clinical Research in Cardiology — The Use of Intracoronary Pyruvate as an Adjunct to Catecholamines and Intra-Aortic Balloon Pump in Cardiogenic Shock: Positive Impacts on Hemodynamics
6. Blood Cancer Journal — The innovative tyrosine kinase inhibitor AKN-028 demonstrates considerable antileukemic effects in both cell lines and primary cultures of acute myeloid leukemia.
7. ASH SCD Guidelines: Transfusion Support - Hematology.org
8. Safety and efficacy of mitapivat in sickle cell disease (RISE UP): results from the phase 2 portion of a global, double-blind, randomised, placebo-controlled trial - ScienceDirect